Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A

Neurobiology of Disease

Volumn 38, Issue 1, 2010, Pages 78-84

  Kohl, Bianca ^a   Groh, Janos ^a   Wessig, Carsten ^a   Wiendl, Heinz ^a   Kroner, Antje ^a,b   Martini, Rudolf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

CMT; Co inhibitory molecule; Demyelination; Macrophages; PD 1; Peripheral nerves; RAG 1; Schwann cells; T lymphocytes

Indexed keywords

MUTANT PROTEIN; MYELIN; PERIPHERAL MYELIN PROTEIN 22;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE COURSE; HEREDITARY MOTOR SENSORY NEUROPATHY; IMMUNE STATUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET CELL;

ANIMALS; AXONS; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CHARCOT-MARIE-TOOTH DISEASE; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELIN PROTEINS; MYELIN SHEATH; PERIPHERAL NERVES; T-LYMPHOCYTES;

EID: 77549084418     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.01.001     Document Type: Article

References (40)

1. Berghoff M., Samsam M., Muller M., Kobsar I., Toyka K.V., Kiefer R., Maurer M., and Martini R. Neuroprotective effect of the immune system in a mouse model of severe dysmyelinating hereditary neuropathy: enhanced axonal degeneration following disruption of the RAG-1 gene. Mol. Cell. Neurosci. 28 (2005) 118-127
2. Burns J., Ouvrier R.A., Yiu E.M., Joseph P.D., Kornberg A.J., Fahey M.C., and Ryan M.M. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 8 (2009) 537-544
3. Carenini S., Mäurer M., Werner A., Blazyca H., Toyka K.V., Schmid C.D., Raivich G., and Martini R. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in P0. J. Cell. Biol. 152 (2001) 301-308
4. Crawford T.O., and Griffin J.W. Morphometrical and ultrastructural evaluation of the sural nerve in children with Charcot-Marie-Tooth: implication for pathogenesis and treatment. Ann. Neurol. 30 (1991) 500
5. Fischer S., Kleinschnitz C., Müller M., Kobsar I., Ip C.W., Rollins B.J., and Martini R. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol. Cell. Neurosci. 37 (2008) 359-366
6. Fischer S., Weishaupt A., Troppmair J., and Martini R. Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway. Glia 56 (2008) 836-843
7. Ginsberg L., Malik O., Kenton A.R., Sharp D., Muddle J.R., Davis M.B., Winer J.B., Orrell R.W., and King R.H. Coexistent hereditary and inflammatory neuropathy. Brain 127 (2004) 193-202
8. Grandis M., and Shy M.E. Current Therapy for Charcot-Marie-Tooth Disease. Curr. Treat. Options Neurol. 7 (2005) 23-31
9. Huxley C., Passage E., Manson A., Putzu G., Figarella-Branger D., Pellisier J.F., and Fontes M. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum. Mol. Gent. 5 (1996) 563-569
10. Huxley C., Passage E., Robertson A.M., Youl B., Huston S., Manson A., Sabéran-Djoniedi D., Figarella-Branger D., Pellisier J.F., Thomas P.K., and Fontes M. Correlation between varying levels and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum. Mol. Genet. 7 (1998) 449-458
11. Ip C.W., Kroner A., Bendszus M., Leder C., Kobsar I., Fischer S., Wiendl H., Nave K.A., and Martini R. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J. Neurosci. 26 (2006) 8206-8216
12. Ip C.W., Kroner A., Fischer S., Berghoff M., Kobsar I., Mäurer M., and Martini R. Role of immune cells in animal models for inherited peripheral neuropathies. Neuromol. Med. 8 (2006) 175-189
13. Ip C.W., Kroner A., Crocker P.R., Nave K.A., and Martini R. Sialoadhesin deficiency ameliorates myelin degeneration and axonopathic changes in the CNS of PLP overexpressing mice. Neurobiol. Dis. 25 (2007) 105-111
14. Jani-Acsadi A., Krajewski K., and Shy M.E. Charcot-Marie-Tooth neuropathies: diagnosis and management. Semin. Neurol. 28 (2008) 185-194
15. Kaya F., Belin S., Bourgeois P., Micaleff J., Blin O., and Fontes M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul. Disord. 17 (2007) 248-253
16. Kobsar I., Berghoff M., Samsam M., Wessig C., Maurer M., Toyka K.V., and Martini R. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126 (2003) 804-813
17. Kobsar I., Hasenpusch-Theil K., Wessig C., Muller H.W., and Martini R. Evidence for macrophage-mediated myelin disruption in an animal model for Charcot-Marie-Tooth neuropathy type 1A. J. Neurosci. Res. 81 (2005) 857-864
18. Kobsar I., Oetke C., Kroner A., Wessig C., Crocker P., and Martini R. Attenuated demyelination in the absence of the macrophage-restricted adhesion molecule sialoadhesin (Siglec-1) in mice heterozygously deficient in P0. Mol. Cell. Neurosci. 31 (2006) 685-691
19. Kohl, B., Fischer, S., Groh, J., Wessig, C., Martini, R., 2009. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-Tooth 1A. Am J Pathol 174 accepted
20. Kroner A., Schwab N., Ip C.W., Leder C., Nave K.A., Maurer M., Wiendl H., and Martini R. PD-1 regulates neural damage in oligodendroglia-induced inflammation. PLoS ONE e4405 (2009) 4
21. Kroner A., Schwab N., Ip C.W., Ortler S., Gobel K., Nave K.A., Maurer M., Martini R., and Wiendl H. Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. Am. J. Pathol. 174 (2009) 2290-2299
22. Kroner A., Schwab N., Ip C.W., Sommer C., Wessig C., Wiendl H., and Martini R. The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. Neurobiol. Dis. 33 (2009) 96-103
23. Kroner, A., Ip, C.W., Thalhammer, J., Nave, K.A., Martini, R., 2010. Ectopic T-cell specificity and absence of perforin and granzyme B alleviate neural damage in oligodendrocyte mutant mice. Am J Pathol. 176, 549-555.
24. Leder C., Schwab N., Ip C.W., Kroner A., Nave K.A., Dornmair K., Martini R., and Wiendl H. Clonal expansions of pathogenic CD8+ effector cells in the CNS of myelin mutant mice. Mol. Cell. Neurosci. 36 (2007) 416-424
25. Magyar J.P., Martini R., Ruelicke T., Aguzzi A., Adlkofer K., Dembic Z., Zielasek J., Toyka K.V., and Suter U. Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage. J. Neurosci. 16 (1996) 5351-5360
26. Martini R., and Toyka K.V. Immune-mediated components of hereditary demyelinating neuropathies: lessons from animal models and patients. Lancet Neurol. 3 (2004) 457-465
27. Martini R., Fischer S., Lopez-Vales R., and David S. Interactions between Schwann cells and macrophages in injury and inherited demyelinating disease. Glia 56 (2008) 1566-1577
28. Mäurer M., Schmid C.D., Bootz F., Zielasek J., Toyka K.V., Oehen S., and Martini R. Bone marrow transfer from wild type mice reverts the beneficial effect of genetically-mediated immune deficiency in myelin mutants. Mol. Cell. Neurosci. 17 (2001) 1094-1101
29. Meyer zu Horste G., Prukop T., Liebetanz D., Mobius W., Nave K.A., and Sereda M.W. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann. Neurol. 61 (2007) 61-72
30. Micallef J., Attarian S., Dubourg O., Gonnaud P.M., Hogrel J.Y., Stojkovic T., Bernard R., Jouve E., Pitel S., Vacherot F., Remec J.F., Jomir L., Azabou E., Al-Moussawi M., Lefebvre M.N., Attolini L., Yaici S., Tanesse D., Fontes M., Pouget J., and Blin O. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 8 (2009) 1103-1110
31. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., and Papaioannou V.E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68 (1992) 869-877
32. Pareyson D., and Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?. Lancet Neurol. 8 (2009) 1075-1077
33. Passage E., Norreel J.C., Noack-Fraissignes P., Sanguedolce V., Pizant J., Thirion X., Robaglia-Schlupp A., Pellissier J.F., and Fontes M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat. Med. 10 (2004) 396-401
34. Reilly M.M., Munro N., Robinson S., and Hughes R.A.C. Acute inflammatory demyelinating polyradiculoneuropathy in a patient with asymptomatic Charcot-Marie-Tooth disease type 1A. Muscle Nerve S7 (1998) S208
35. Scherer S.S., and Wrabetz L. Molecular mechanisms of inherited demyelinating neuropathies. Glia 56 (2008) 1578-1589
36. Schmid C.D., Stienekemeier M., Oehen S., Bootz F., Zielasek J., Gold R., Toyka K.V., Schachner M., and Martini R. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. J. Neurosci. 20 (2000) 729-735
37. Sereda M.W., Meyer zu Horste G., Suter U., Uzma N., and Nave K.A. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat. Med. 9 (2003) 1533-1537
38. Vital A., Vital C., Julien J., and Fontan D. Occurrence of active demyelinating lesions in children with hereditary motor and sensory neuropathy (HMSN) type I. Acta Neuropathol. 84 (1992) 433-436
39. Vital A., Vital C., Lagueny A., Ferrer X., Ribiere-Bachelier C., Latour P., and Petry K.G. Inflammatory demyelination in a patient with CMT1A. Muscle Nerve 28 (2003) 373-376
40. Zielasek J., Martini R., and Toyka K.V. Functional abnormalities in P0-deficient mice resemble human hereditary neuropathies linked to P0 gene mutations. Muscle Nerve 19 (1996) 946-952